Thermo Fisher Scientific (STU:TN8) Debt-to-Revenue : 0.98 (As of Mar. 2026)


STU:TN8 Thermo Fisher Scientific Inc STU:TN8
82 GF Score
Price €411.80
GF Value €511.44
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Thermo Fisher Scientific Debt-to-Revenue?

Thermo Fisher Scientific STU:TN8 +1.50% 82 Debt-to-Revenue is 0.98 as of Mar. 2026. GuruFocus rates STU:TN8 with a GF Score™ of 82/100 and a GF Value™ of €511.44 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Thermo Fisher Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €2,673 Mil. Thermo Fisher Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €34,661 Mil. Thermo Fisher Scientific's annualized Revenue for the quarter that ended in Mar. 2026 was €38,077 Mil. Thermo Fisher Scientific's annualized Debt-to-Revenue for the quarter that ended in Mar. 2026 was 0.98.

Thermo Fisher Scientific Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Thermo Fisher Scientific's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thermo Fisher Scientific Debt-to-Revenue Chart

Thermo Fisher Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.77 0.82 0.73 0.88

Thermo Fisher Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.81 0.80 0.81 0.98

STU:TN8 vs DHR, IDXX, A: Debt-to-Revenue Comparison

For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thermo Fisher Scientific Debt-to-Revenue vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Thermo Fisher Scientific's Debt-to-Revenue falls into.


STU:TN8
82GF Score
Thermo Fisher Scientific Inc STU:TN8
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thermo Fisher Scientific Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Thermo Fisher Scientific's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3017.182 + 30617.608) / 38051.678
=0.88

Thermo Fisher Scientific's annualized Debt-to-Revenue for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2672.85 + 34661.415) / 38077.3
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.98 mean?
Thermo Fisher Scientific (STU:TN8) has a Debt-to-Revenue of 0.98 as of Mar. 2026.
Is Thermo Fisher Scientific's Debt-to-Revenue too high?
Thermo Fisher Scientific's current Debt-to-Revenue is 0.98. Overall, Thermo Fisher Scientific has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Debt-to-Revenue compare to DHR and IDXX?
Thermo Fisher Scientific's Debt-to-Revenue of 0.98 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Medical Diagnostics & Research company?
A good Debt-to-Revenue depends on the Medical Diagnostics & Research industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Thermo Fisher Scientific's current Debt-to-Revenue is 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (STU:TN8) is currently considered Modestly Undervalued. The stock's GF Value™ is €511.44, compared to a current price of €411.80 — trading 19.5% below its estimated fair value. The current Debt-to-Revenue is 0.98. Thermo Fisher Scientific's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Thermo Fisher Scientific (STU:TN8), the current Debt-to-Revenue is 0.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thermo Fisher Scientific (STU:TN8) Overvalued in 2026?

Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued. The current stock price of €411.80 is trading 19.5% below its estimated GF Value™ of €511.44. GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.

Key valuation signals for STU:TN8:

  • Debt-to-Revenue: 0.98
  • GF Value™: €511.44 vs. price of €411.80 (19.5% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the STU:TN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Thermo Fisher Scientific Business Description

Address 168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
82GF Score

Get the complete analysis for STU:TN8

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€411.80
Price
€511.44
GF Value